World Investment Advisors LLC Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

World Investment Advisors LLC raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 3.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,132 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the quarter. World Investment Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $371,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Fifth Third Bancorp increased its position in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 354 shares during the period. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $52,000. Meeder Asset Management Inc. increased its position in shares of Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $96,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 0.4 %

NASDAQ:ARWR opened at $22.27 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a one year low of $17.05 and a one year high of $39.83. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The company’s 50-day simple moving average is $21.06 and its 200 day simple moving average is $23.14. The firm has a market capitalization of $2.77 billion, a P/E ratio of -4.44 and a beta of 0.91.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ARWR. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Sanford C. Bernstein reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. Finally, Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.